Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-129 plus ensartinib in MET-amplified/overexpressing advanced solid tumors
CTR20254638Phase 2Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Feb 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pamvatamig, ensartinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Betta Pharmaceuticals. Started Feb 2026; status: active.
02
Drugs
pamvatamigensartinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20254638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254638.